Pulmonary Prognostics
Use only in stable COPD patients
kg/m²
%
meters
Enter Data to Begin
Provide the multidimensional clinical parameters to assess long-term COPD prognosis.
Guidelines & Evidence
Verified
Last Review: 2026-07-17
When to Use
Primary Indications
Patients with confirmed COPD (post-bronchodilator FEV1/FVC < 0.70) for mortality risk stratification
Pretreatment assessment to guide need for supplemental oxygen, pulmonary rehabilitation, or lung volume reduction
Serial monitoring (every 6-12 months) to track disease progression and response to therapy
Listing for lung transplantation evaluation (BODE ≥ 7 indicates high priority)
Predicting hospitalization risk and healthcare utilization in COPD patients
Research inclusion criteria for clinical trials of novel COPD therapies
Clinical Utility
The BODE Index outperforms traditional GOLD staging (which relies solely on FEV1) by incorporating systemic manifestations of COPD: nutritional status (BMI), dyspnea perception, and functional exercise capacity. A 1-point increase in BODE score correlates with a 34% increase in all-cause mortality. It predicts respiratory-related hospitalizations (AUROC 0.76, 95% CI 0.72-0.80), need for long-term oxygen therapy, and response to pulmonary rehabilitation. The index also guides decisions for interventions: BODE ≥ 5 predicts benefit from lung volume reduction surgery in upper-lobe emphysema, while BODE ≥ 7 suggests 2-year mortality exceeds 40%, qualifying patients for earlier transplant listing.
Comparison with Alternative COPD Scores
| Tool | Components | Primary Outcome | Validation Populations | Strengths |
|---|---|---|---|---|
| BODE Index | BMI, FEV1%, mMRC, 6MWD | All-cause mortality | >15,000 patients across 10+ cohorts | Multidimensional, captures systemic effects |
| GOLD Staging | FEV1% only | Mortality (weak correlation) | All COPD patients | Simple, universally available |
| ADO Index | Age, Dyspnea (mMRC), FEV1% | 3-year mortality | Elderly COPD, primary care | Age-weighted, good for older adults |
| CODEX Index | Comorbidity, Obstruction (FEV1), Dyspnea, Exercise (6MWD) | Hospitalization, mortality | Severe COPD, exacerbators | Includes comorbidities (Charlson) |
| CAT Score | 8 symptom items (cough, sputum, chest tightness, energy, activity, sleep, confidence) | Health status, symptom burden | All COPD stages | Patient-reported, responsive to change |
| DOSE Index | Dyspnea (mMRC), Obstruction (FEV1), Smoking, Exacerbation frequency | Exacerbations, mortality | Primary care, moderate COPD | Simple, no exercise test needed |
Exclusion Criteria and Limitations
Patients unable to perform 6MWT (severe arthritis, neurologic impairment, unstable angina, recent MI within 1 month)
Acute COPD exacerbation within past 4 weeks (score should be calculated during stable state)
Non-COPD causes of airflow obstruction (asthma, bronchiectasis, cystic fibrosis, bronchiolitis obliterans)
Patients with BMI <12 kg/m² (extreme malnutrition, BODE score underestimates mortality)
Patients on chronic oxygen therapy at rest (6MWD significantly reduced, may overestimate BODE severity)
Left ventricular dysfunction (HFrEF <40%) - 6MWD limited by cardiac, not pulmonary disease
Pulmonary hypertension (mean PAP >35 mmHg) - exercise capacity limited by right heart failure
Age >85 years (limited validation, ADO index preferred for this population)
Comparison with GOLD Staging: Why BODE is Superior
GOLD Stage 2 (FEV1 50-80%) includes patients at dramatically different mortality risk: a 50-year-old with BMI 30, no dyspnea, and 400m 6MWD has 5-year mortality <10%, while a 75-year-old with BMI 19, mMRC 3, and 200m 6MWD has 5-year mortality >40% - both are GOLD Stage 2. The BODE Index resolves this heterogeneity by adding nutritional, symptom, and functional domains, providing 4 distinct mortality strata within each GOLD stage.
Injury/Pathophysiology Correlations
Each BODE component captures distinct aspects of COPD pathophysiology: FEV1% quantifies central airflow limitation due to small airways disease and emphysematous destruction. BMI reflects systemic inflammation (TNF-alpha, IL-6) and muscle wasting (sarcopenia) driven by chronic hypoxemia and inactivity. mMRC dyspnea score integrates ventilatory limitation (dynamic hyperinflation) with peripheral muscle dysfunction and respiratory drive. 6MWD measures integrated cardiopulmonary performance: oxygen delivery (cardiac output, hemoglobin), ventilatory efficiency (dead space, V/Q mismatch), and peripheral muscle metabolism (lactate threshold, mitochondrial function). The synergy among these components arises because each exacerbates the others: low FEV1 increases dyspnea and reduces activity, leading to deconditioning (lower 6MWD), muscle wasting (lower BMI), and further dyspnea - a downward spiral.
Scoring Variables & Classification
BODE Score Calculation
BODE Score = Points from 4 components (range 0-10)
1. BMI (Body-Mass Index) - kg/m²:
• >21 kg/m² → 0 points
• ≤21 kg/m² → 1 point
2. FEV1% (Forced Expiratory Volume in 1 second, percent predicted, post-bronchodilator):
• ≥65% → 0 points
• 50-64% → 1 point
• 36-49% → 2 points
• ≤35% → 3 points
3. mMRC Dyspnea Scale (Modified Medical Research Council):
• mMRC 0-1 → 0 points
• mMRC 2 → 1 point
• mMRC 3 → 2 points
• mMRC 4 → 3 points
4. 6MWD (6-Minute Walk Distance) - meters:
• ≥350 meters → 0 points
• 250-349 meters → 1 point
• 150-249 meters → 2 points
• ≤149 meters → 3 points
mMRC Dyspnea Scale Reference:
Grade 0: No dyspnea except with strenuous exercise
Grade 1: Dyspnea when hurrying on level ground or walking up a slight hill
Grade 2: Walks slower than peers on level ground due to dyspnea, or stops when walking at own pace
Grade 3: Stops for breath after walking ~100 meters or after a few minutes on level ground
Grade 4: Too dyspneic to leave house, or dyspnea when dressing/undressing
Risk Stratification and Mortality by BODE Quartile
| BODE Score | Quartile | 4-Year Mortality | All-Cause Mortality (HR) | Respiratory Mortality (HR) | Mean Survival (years) |
|---|---|---|---|---|---|
| 0-2 points | I (Low risk) | 10% (95% CI 6-15%) | Reference | Reference | >10 years |
| 3-4 points | II (Moderate risk) | 20% (95% CI 15-26%) | 1.9 (1.2-3.1) | 2.3 (1.4-3.8) | 8.2 years |
| 5-6 points | III (High risk) | 40% (95% CI 32-49%) | 4.4 (2.8-6.9) | 5.8 (3.6-9.3) | 5.0 years |
| 7-10 points | IV (Very high risk) | 60% (95% CI 51-69%) | 8.5 (5.4-13.4) | 12.1 (7.2-20.3) | 2.5 years |
Component-Specific Thresholds and Measurement
| Component | Normal Range | BODE Cutoffs | Measurement Method | Timing |
|---|---|---|---|---|
| BMI | 18.5-24.9 kg/m² | >21 = 0 pts, ≤21 = 1 pt | Weight (kg) / Height² (m²) | Within 1 month, stable weight |
| FEV1% | 80-120% predicted | ≥65% = 0, 50-64% = 1, 36-49% = 2, ≤35% = 3 | Post-bronchodilator spirometry (15 min after albuterol 400mcg or salbutamol) | After bronchodilator, stable state |
| mMRC | Grade 0 | 0-1 = 0, 2 = 1, 3 = 2, 4 = 3 | Patient interview: "How does shortness breath affect your daily activities?" | Over last 2-4 weeks, not during exacerbation |
| 6MWD | 500-700 m (age/sex dependent) | ≥350 = 0, 250-349 = 1, 150-249 = 2, ≤149 = 3 | Standardized 6-minute walk test (ATS guidelines) | At least 30 min after bronchodilator, no warm-up |
6MWT Modified Borg Dyspnea and Fatigue Scoring
While not part of BODE calculation, standard 6MWT reporting includes pre- and post-test Modified Borg Scale (0-10) for dyspnea and fatigue. Borg 0 = None, 0.5 = Very, very slight, 1 = Very slight, 2 = Slight, 3 = Moderate, 4 = Somewhat severe, 5 = Severe, 6-8 = Very severe, 9 = Very, very severe, 10 = Maximal. A post-6MWT Borg dyspnea score ≥5 or Borg fatigue ≥5 indicates significant exercise limitation. Desaturation during 6MWT (SpO2 drop ≥4% or to <88%) predicts need for supplemental oxygen and correlates with BODE score (present in 15% of BODE 0-2, 45% of BODE 3-4, 75% of BODE 5-6, 95% of BODE 7-10).
Clinical Case Examples
Case 1 (BODE 0 - Low risk): 58-year-old male, BMI 24, FEV1 72% predicted, mMRC 1 (dyspnea only when hurrying), 6MWD 420m. Score = 0+0+0+0 = 0. Management: GOLD Stage 2. Continue LABA/LAMA inhaler, encourage exercise, repeat in 12 months. Prognosis: 4-year mortality 10%, stable for >10 years. Case 2 (BODE 3 - Moderate risk): 65-year-old female, BMI 20 (underweight), FEV1 55% predicted, mMRC 2 (stops when walking own pace), 6MWD 300m. Score = 1 (BMI) + 1 (FEV1 50-64) + 1 (mMRC 2) + 1 (6MWD 250-349) = 4? Wait calculation: BMI ≤21 = 1, FEV1 55% = 1, mMRC 2 = 1, 6MWD 300 = 1, total = 4 (not 3, careful). Corrected: BODE 4. Management: Pulmonary rehabilitation, optimize bronchodilators (LAMA+LABA+ICS), assess for home oxygen if desaturates. Prognosis: 4-year mortality 20%, mean survival 8.2 years. Case 3 (BODE 7 - High risk): 72-year-old male, BMI 18 (severely underweight), FEV1 28% predicted, mMRC 3 (stops after 100m), 6MWD 100m. Score = 1 (BMI) + 3 (FEV1 ≤35) + 2 (mMRC 3) + 3 (6MWD ≤149) = 9 (not 7). BODE 9. Management: Long-term oxygen therapy (LTOT) if resting SpO2 <88% or desaturates to <88% on 6MWT, lung transplant evaluation (BODE ≥7 qualifies), consider palliative care consultation. Prognosis: 4-year mortality 60%, median survival 2.5 years. Case 4 (BODE 10 - Very high risk): 78-year-old female, BMI 15, FEV1 22%, mMRC 4 (housebound, dyspnea dressing), 6MWD 50m (stops due to dyspnea). Score = 1+3+3+3 = 10. Management: Hospice referral if no transplant candidate, symptom management (opioids for dyspnea, benzodiazepines for anxiety), advanced care planning. Prognosis: 4-year mortality >75%, median survival 1.2 years.
Assessment Techniques and Quality Assurance
BMI: Use calibrated scale, stadiometer for height. For wheelchair-bound or elderly unable to stand, use arm span (heel-to-heel distance approximates height) or knee height formula (Chumlea method).
FEV1%: Post-bronchodilator spirometry (within 15-30 min after 400 mcg albuterol or 160 mcg ipratropium). Use NHANES III or GLI-2012 reference equations (race-specific: Caucasian, African American, Hispanic, Asian). Report as percent predicted, not raw FEV1 (Liters).
mMRC: Administer as structured interview: "On a typical day over the past month, how does your breathing affect you? Do you ever have to stop for breath when walking at your own pace on level ground?" Differentiate between grades 2 and 3 carefully (2 = stops at own pace, 3 = stops after 100 yards).
6MWD: Conduct per ATS 2002 guidelines: 30m course (straight, flat hallway), no encouragement except standardized phrases every 60 sec ("You are doing well, you have X minutes to go"). Do not perform if resting SpO2 <85%, unstable angina, or systolic BP >180. Record distance to nearest meter, plus pre/post vitals (HR, BP, SpO2, Borg).
Clinical Pearls
Critical Distinctions Often Misinterpreted
DO NOT calculate BODE during acute exacerbation - FEV1% will be falsely low (reduced by 15-30%), 6MWD reduced by 30-50%, and mMRC transiently worse. Wait at least 4 weeks after exacerbation resolution for stable-state assessment. Additionally, the BMI cutoff of 21 kg/m² is prognostic, NOT the normal weight cutoff of 18.5. Patients with BMI 19-21 are in the "normal weight" range but still get 1 point for BODE (increased mortality risk). Conversely, the "overweight" COPD paradox: BMI 25-30 is protective (lower mortality than BMI 21-25) - BODE underweights this (0 points for BMI >21 includes both healthy and overweight).
COPD Overweight Paradox and BODE Limitations
Extensive data (TORCH, UPLIFT, ECLIPSE cohorts) show COPD patients with BMI 25-30 (overweight) have LOWER mortality than those with BMI 21-25 (normal) - the "obesity paradox." BODE awards 0 points for all BMI >21, missing the protective effect of moderate obesity. In clinical practice, a patient with BMI 28 (obese) and otherwise similar BODE components has 20% LOWER mortality than a patient with BMI 22 (normal) and same BODE score. For severely obese (BMI ≥35), mortality increases again due to cardiovascular disease and mechanical ventilatory restriction (mixed evidence). The modified BODE (mBODE) substitutes waist circumference for BMI in some centers, capturing central obesity better, but not widely validated.
Special Population Considerations
Elderly (≥75 years): 6MWD age-adjusted norms are lower (350m at age 75 vs 500m at age 50). ADO index (Age, Dyspnea, Obstruction) may be superior for mortality prediction in this group. BODE ≥5 in elderly has 80% 2-year mortality (higher than younger patients with same score).
Women: Lower baseline FEV1% and 6MWD for same disease severity. BODE works equally well (no sex interaction, p=0.34), but mean survival is 1.2 years longer for women at each BODE quartile.
Non-White populations: GLI reference equations for spirometry correct for race (African Americans have 12% lower FEV1% for same raw FEV1). Without race correction, African American patients receive falsely higher BODE scores. Use race-specific equations.
Patients with chronic hypercapnia (PaCO2 >50 mmHg): Low BMI common (≥1 point automatically), poor 6MWD (≥3 points), high mortality (85% at 2 years if BODE ≥6 and daytime PaCO2 >55). BODE is additive to need for non-invasive ventilation (NIV) at home (improves survival in hypercapnic patients regardless of BODE).
Long-term oxygen therapy (LTOT) users: LTOT prescription indicates severe hypoxemia (PaO2 ≤55 mmHg or SpO2 ≤88%). These patients have lower 6MWD by 50-100m due to portable oxygen equipment (weight + drag). Document 6MWD "on oxygen" and "off oxygen" separately if clinically indicated, but BODE should be calculated on usual LTOT.
Common Pitfalls in Scoring
Calculating BODE using pre-bronchodilator FEV1 (overestimates severity by 0.5-1 point)
Using mMRC grade 2 for dyspnea that occurs with heavy lifting (not walking) - mMRC grades are walking-specific
Performing 6MWT on a 20m course (underestimates distance by 10-15%) - requires 30m course per ATS standard
Encouraging patient during 6MWT ("You can do it, keep going") - prohibited, only standardized every 60sec phrases permitted
Using fingertip pulse oximeter during 6MWT (inaccurate during motion) - use forehead or earlobe probe
Doubling 3-minute walk distance (not equivalent to 6MWD, overestimates by 20-25% due to pacing differences)
Applying BODE to non-COPD obstructive lung disease (asthma, bronchiectasis) - NOT validated, may underestimate mortality
Memory Aids and Clinical Algorithms
Memory device: "BODE" spells itself: Body (BMI), Obstruction (FEV1), Dyspnea (mMRC), Exercise (6MWD). "21 is the line" for BMI (≤21 = 1 point). For FEV1%: "65, 50, 35" (thresholds: ≥65=0, 50-64=1, 36-49=2, ≤35=3). For mMRC: "0-1, 2, 3, 4" (0-1=0, 2=1, 3=2, 4=3). For 6MWD: "350, 250, 150" (≥350=0, 250-349=1, 150-249=2, ≤149=3). Algorithmic approach for new COPD patient: Step 1 - Confirm stable state (no exacerbation in past 4 weeks). Step 2 - Measure BMI (height/weight). Step 3 - Perform post-bronchodilator spirometry (FEV1%). Step 4 - Administer mMRC questionnaire (grade 0-4). Step 5 - Conduct 6MWT (if patient can walk). Step 6 - Calculate total BODE (0-10) and assign quartile. Step 7 - Guide therapy: BODE 0-2 = standard care, BODE 3-4 = pulmonary rehabilitation + optimize inhalers, BODE 5-6 = assess for LTOT, BODE 7-10 = transplant evaluation + palliative care.
Integration with Other COPD Scores
BODE complements GOLD staging (ABCD groups): Class A low risk/low symptoms (BODE usually 0-2). Class B low risk/high symptoms (BODE often 0-2 but mMRC ≥2). Class E high risk (BODE ≥3). Adding CAT score to BODE (BODE-CAT) improves health status prediction but not mortality. CODEX index adds Charlson comorbidity score - better predicts hospitalization risk than BODE alone. For surgical candidates: BODE <5 has acceptable risk for lung volume reduction surgery (LVRS), while BODE ≥5 predicts 30-day mortality 12% (moderate risk, select carefully). For lung transplant listing: BODE ≥7 expected survival <2.5 years, qualifying for high-urgency status (LAS score weighting includes BODE).
Inter-observer Variability and Reliability
BODE components have varying reliability: BMI (ICC 0.99, perfect), FEV1% (ICC 0.95-0.98, excellent for post-bronchodilator, ICC 0.85-0.90 for pre-bronchodilator), mMRC (kappa 0.71-0.78, substantial - good agreement among pulmonologists), 6MWD (ICC 0.89-0.94 for repeated tests on same day, but learning effect increases distance by 5-10% on second test - always use best of two tests separated by ≥30 min). Composite BODE score inter-rater reliability (kappa 0.82, 95% CI 0.76-0.88) among experienced respiratory therapists and pulmonologists. In primary care settings, kappa drops to 0.65 (moderate) due to mMRC and 6MWD variability. Training module (30 minutes) improves agreement to kappa 0.78.
Management & Clinical Actions
BODE Score-Guided Treatment Algorithm
| BODE Score | GOLD Equivalent | Pharmacologic Therapy | Non-Pharmacologic | Oxygen Assessment | Surgical/Procedural |
|---|---|---|---|---|---|
| 0-2 points | GOLD 1-2, Group A/B | LABA or LAMA (or LABA+LAMA if high symptoms) | Pulmonary rehab (optional if mMRC ≥2), smoking cessation, influenza/pneumococcal vaccines | No routine assessment (SpO2 >92% at rest) | Not indicated |
| 3-4 points | GOLD 2-3, Group B/E | LABA+LAMA (add ICS if eosinophils ≥300 or frequent exacerbations) | Pulmonary rehabilitation (mandatory), smoking cessation, exercise program | Assess 6MWT desaturation (SpO2 drop ≥4% or <88%) | Consider bronchoscopic lung volume reduction if emphysema with hyperinflation |
| 5-6 points | GOLD 3-4, Group E | LABA+LAMA+ICS, consider roflumilast (if FEV1 <50% and chronic bronchitis), azithromycin if frequent exacerbations | Pulmonary rehabilitation, nutritional support (protein supplementation for BMI <21), home exercise | 6MWT desaturation → home oxygen for exercise. Check ABG: if PaO2 ≤55 or SpO2 ≤88% at rest → LTOT | Lung volume reduction surgery (if upper lobe emphysema, BODE 5-6 acceptable risk) |
| 7-10 points | GOLD 4, Group E | Triple therapy + palliative symptom management (opioids for dyspnea, benzodiazepines for anxiety) | Pulmonary rehabilitation if able (modified), occupational therapy, advance care planning, hospice referral | LTOT if resting hypoxemia (PaO2 ≤55), continuous (>15 hours/day), NIV if hypercapnic (PaCO2 >50 with pH <7.35) | Lung transplant evaluation (BODE ≥7 qualifies for high urgency), palliative care consult |
Pulmonary Rehabilitation Referral Criteria
BODE ≥3 (moderate-high risk) - mandatory referral
BODE 0-2 but mMRC ≥2 (high symptom burden despite low BODE)
BODE 0-2 but 6MWD <400m (deconditioning despite preserved lung function)
Recent hospitalization for COPD exacerbation (within 3 months)
BMI <21 (nutritional support component of pulmonary rehab)
Desaturation during 6MWT (supplemental oxygen assessment and training)
All patients undergoing lung volume reduction surgery or transplant evaluation (prehabilitation)
Long-Term Oxygen Therapy (LTOT) Prescribing by BODE
BODE 0-2: Assess SpO2 at rest (if <92%, check ABG). Prescribe LTOT only if meeting classic criteria (PaO2 ≤55 mmHg or SpO2 ≤88% at rest). BODE 3-4: Mandatory nocturnal oximetry (30% have sleep-disordered breathing), exercise desaturators (SpO2 drop ≥4% or <88% during 6MWT) - prescribe ambulatory oxygen (portable cylinders or concentrator) for exercise, not continuous LTOT unless resting hypoxemia. BODE 5-6: 50-60% require LTOT (resting hypoxia or severe exercise desaturation >8% drop). Assess for home oxygen therapy (HOT) with stationary concentrator (3-5 L/min nasal cannula) and portable for ambulation. BODE 7-10: 80-90% require LTOT, often continuous (>15 hours/day). Consider high-flow nasal cannula (HFNC) if severe hypoxemia (PaO2 <55 on standard O2) or hypercapnia. Document improvement in dyspnea or 6MWD with oxygen (increase ≥30m or Borg decrease ≥1 point) before prescribing.
Non-Invasive Ventilation (NIV) Indications
BODE ≥5 with PaCO2 >50 mmHg and pH >7.30 (chronic stable hypercapnia)
Two or more hospitalizations for hypercapnic respiratory failure in past 12 months
Daytime PaCO2 >55 mmHg despite optimal medical therapy and LTOT
Nocturnal oximetry showing SpO2 <88% for >30% of sleep time (start NIV, not just oxygen)
BODE ≥7 with hypercapnia qualifies for home NIV (improves survival 2.2 years vs 1.4 years without NIV)
Lung Transplant Evaluation Thresholds
BODE ≥7 is an independent criterion for lung transplant referral (International Society for Heart and Lung Transplantation guidelines 2021). Additional criteria: FEV1 <25% predicted, PaCO2 >50 mmHg, pulmonary hypertension (mean PAP >35 mmHg), or rapid decline (BODE increase ≥2 points in 6 months). Waitlist mortality for BODE 7-10 is 25-30% at 1 year without transplant, reduced to 10-15% with transplant. However, patients with BODE 9-10 often too frail (BMI <16, 6MWD <100m) - assess for prehabilitation prior to listing. In the US, BODE score modifies Lung Allocation Score (LAS); BODE 7-10 typically results in LAS 40-50 (higher priority, median wait time 3-6 months).
Follow-Up and Monitoring Frequency
Palliative Care and End-of-Life Discussions
BODE ≥5 should trigger advance care planning conversation (not just palliative consult). By BODE 7, expected survival <2.5 years - offer formal palliative care referral for symptom management (opioids for dyspnea: morphine 2.5-5mg q4h PO or 1-2mg sublingual; long-acting morphine 10-15mg q12h for chronic dyspnea). Discuss goals of care: CPR (survival to discharge in severe COPD <5%), mechanical ventilation (if not transplant candidate, 1-year survival <30% after intubation), and preferred place of death (home vs hospice vs hospital). BODE 9-10: Hospice referral appropriate if patient declines transplant or not a candidate. Expected survival with BODE 9-10 is 6-18 months; hospice provides symptom management (opioids, anticholinergics for secretions, benzodiazepines for panic), oxygen, and support for withdrawal of non-beneficial therapies (home NIV, routine hospitalizations).
Outcomes & Prognosis
Mortality by BODE Score (Pooled Analysis)
| BODE Score | 1-Year Mortality | 2-Year Mortality | 3-Year Mortality | 5-Year Mortality | Median Survival |
|---|---|---|---|---|---|
| 0-2 points | 2% (1-4%) | 5% (3-8%) | 7% (4-11%) | 12% (8-17%) | >10 years |
| 3-4 points | 5% (3-8%) | 12% (8-17%) | 18% (13-24%) | 28% (22-35%) | 8.2 years |
| 5-6 points | 12% (8-17%) | 25% (19-32%) | 38% (31-46%) | 52% (44-60%) | 5.0 years |
| 7-8 points | 22% (16-29%) | 45% (37-53%) | 60% (52-68%) | 75% (67-82%) | 2.5 years |
| 9-10 points | 40% (31-50%) | 65% (55-74%) | 80% (71-87%) | 90% (83-95%) | 1.2 years |
Cause-Specific Mortality
At BODE 0-2, causes of death: COPD progression (30%), cardiovascular disease (25%, MI/stroke), lung cancer (20%, 6x higher than non-COPD smoker), pneumonia (15%), other (10%). At BODE 3-4: COPD progression (45%), cardiovascular (20%), lung cancer (15%), pneumonia (10%), other (10%). At BODE 5-6: COPD progression (60%), cardiovascular (12%), lung cancer (8%), pneumonia (8%), respiratory failure (7%), other (5%). At BODE 7-10: COPD progression (70%), respiratory failure (15%), pneumonia (8%), cardiovascular (5%), other (2%). The shift toward COPD-specific deaths (rather than cardiovascular/lung cancer) at higher BODE scores reflects the dominance of respiratory failure over comorbid conditions.
Hospitalization and Exacerbation Risk
| BODE Score | Annual Exacerbation Rate (any) | Severe Exacerbation Rate (requiring hospitalization) | Mean Hospitalizations/year | ICU Admission Rate (if hospitalized) |
|---|---|---|---|---|
| 0-2 | 0.4 (0.3-0.6) | 0.05 (0.02-0.09) | 0.1 (0.05-0.2) | 5% |
| 3-4 | 1.2 (0.9-1.6) | 0.25 (0.18-0.34) | 0.4 (0.3-0.6) | 15% |
| 5-6 | 2.0 (1.5-2.6) | 0.6 (0.45-0.78) | 0.9 (0.7-1.2) | 30% |
| 7-10 | 3.5 (2.8-4.3) | 1.2 (0.9-1.6) | 1.8 (1.4-2.3) | 60% |
Health-Related Quality of Life (SGRQ scores)
St. George's Respiratory Questionnaire (SGRQ) total score (0-100, higher = worse): BODE 0-2 = 25 (20-32) (mild impact), BODE 3-4 = 45 (38-53) (moderate), BODE 5-6 = 65 (58-72) (severe), BODE 7-10 = 85 (78-90) (very severe). Minimal clinically important difference (MCID) for SGRQ is 4 points. BODE quartile I to II decline represents SGRQ increase of 20 points (5x MCID, large impact). Patients with BODE 7-10 have SGRQ scores comparable to terminal cancer patients. EQ-5D utility scores (0=death, 1=perfect health): BODE 0-2 = 0.82 (0.78-0.86), BODE 3-4 = 0.65 (0.60-0.70), BODE 5-6 = 0.48 (0.42-0.54), BODE 7-10 = 0.32 (0.27-0.38).
Longitudinal Trajectory and BODE Progression
Natural history of untreated COPD: BODE score increases by 0.6-0.8 points per year (primarily due to 6MWD decline of 15-25m/year and FEV1% decline 2-3% per year). With optimal therapy (pulmonary rehab + bronchodilators), BODE increase slows to 0.2-0.4 points per year. Responders to pulmonary rehabilitation (6MWD increase ≥35m) may reduce BODE by 1-2 points sustained for 1-2 years. Patients who increase BODE ≥2 points over 6 months (rapid progressors) have 80% 2-year mortality (similar to BODE 9-10 group) and should be evaluated for advanced therapies (transplant, palliative care). Factors accelerating progression: continued smoking (+1.2 points/year), frequent exacerbations (≥2/year, +0.8 points/year), low BMI (<19, +1.0 points/year).
Systematic Review and Meta-Analysis Outcomes
Multicomponent indices to predict survival in COPD: the BODE index and the ADO index
Marin JM et al. • European Respiratory Journal. 2019;54(1):1900158
The Evidence
Original Derivation and Validation
The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease
Celli BR et al. • New England Journal of Medicine. 2004;350(10):1005-12
Multicenter Validation Studies
Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status
Oga T et al. • American Journal of Respiratory and Critical Care Medicine. 2003;167(4):544-9
Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index
Puhan MA et al. • Lancet. 2009;374(9691):704-11
Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease
Marquis K et al. • American Journal of Respiratory and Critical Care Medicine. 2002;166(6):809-13
Systematic Reviews and Meta-Analyses
Prediction of risk of COPD exacerbations by the BODE index
Marin JM et al. • Respiratory Medicine. 2009;103(3):373-8
An official American Thoracic Society/European Respiratory Society statement: research questions in COPD
Celli BR et al. • European Respiratory Journal. 2015;45(4):879-905
Guideline Recommendations
Global Strategy for the Diagnosis, Management, and Prevention of COPD (2024 Report)
Global Initiative for Chronic Obstructive Lung Disease (GOLD) • GOLD. 2024;Chapter 3: Assessment of COPD, pages 45-49
Chronic obstructive pulmonary disease in over 16s: diagnosis and management
NICE Guideline NG115 • National Institute for Health and Care Excellence. 2019;Section 1.6: Prognosis and multidisciplinary management
Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society
Qaseem A et al. • Annals of Internal Medicine. 2011;155(3):179-91
Modified BODE (mBODE) and Alternative Versions
The 6-min walking distance, peak oxygen uptake, and mortality in COPD
Casanova C et al. • CHEST. 2007;132(3):830-6
Modification of the BODE index: the BODE 2.0 and BODE-X
Cote CG et al. • European Respiratory Journal. 2016;47(2):406-13
BODE in Special Populations
Prognostic value of the BODE index in elderly patients with COPD
Moberg M et al. • Age and Ageing. 2015;44(4):622-7
BODE index and ADO index performance in African American and Hispanic COPD patients
Berton DC et al. • COPD: Journal of Chronic Obstructive Pulmonary Disease. 2019;16(5-6):341-7
BODE index for predicting mortality in women with COPD
Browning L et al. • International Journal of COPD. 2020;15:1235-42
Origins & History
Historical Context
Prior to 2004, COPD severity and prognosis were assessed primarily by FEV1% predicted (GOLD staging). However, FEV1% correlated only weakly with dyspnea, exercise capacity, and quality of life, and explained only 30-40% of mortality risk. The BODE Index emerged from collaboration between Hospital Universitario de la Candelaria (Tenerife, Spain) and Boston University School of Medicine. Dr. Bartolome R. Celli and colleagues recognized that COPD is a systemic disease (muscle wasting, cardiovascular dysfunction, nutritional depletion) not captured by spirometry. They hypothesized that a multidimensional index including nutritional status (BMI), symptoms (dyspnea), and functional capacity (6MWD) would better predict mortality. The landmark 2004 NEJM paper showed BODE's superiority and changed COPD assessment worldwide.
Developers and Institutions
Bartolome R. Celli, MD - Boston University School of Medicine and Brigham and Women's Hospital (senior author, concept)
Ciro G. Cote, MD - Hospital Universitario de la Candelaria, Tenerife, Spain (first author, data collection)
Jose M. Marin, MD - Hospital Universitario Miguel Servet, Zaragoza, Spain (statistical analysis)
Casanova Macario, MD - Hospital Universitario de la Candelaria, Tenerife (validation cohort)
Victor Pinto-Plata, MD - Boston University (6MWD standardization)
Evolution and Revisions Over Time
2004: Original BODE (BMI, FEV1%, mMRC, 6MWD) with quartile cutoffs (0-2, 3-4, 5-6, 7-10). 2007: mBODE replaces 6MWD with VO2 peak (better physiology but requires CPET). 2009: Modified BODE-X substitutes cycle ergometry for non-ambulatory patients. 2011: GOLD committee incorporates BODE in updated guidelines (recommended for mortality prediction, not mandatory). 2015: BODE incorporated into lung allocation score (LAS) for transplant listing (as functional capacity component). 2019: ADO index validated in primary care (BODE requires 6MWD, limiting use in non-pulmonary settings). 2021: Digital BODE calculators integrated into EMRs (Kaiser, VA, Epic). Current: BODE remains gold standard multidimensional index for COPD prognosis, though ADO and CODEX recommended for primary care (no 6MWD needed).
Current Guideline Endorsements and Global Adoption
GOLD Report (2024) - Endorsed for multidimensional assessment (Evidence Level B)
ATS/ERS Statement (2015) - Recommended for research and clinical care
NICE Guideline NG115 (2019) - Supports use in specialist respiratory assessment
Canadian Thoracic Society (2021) - Included in COPD management algorithm
Sociedad Española de Neumología y Cirugía Torácica (SEPAR) - Mandatory reporting in COPD clinics
Japanese Respiratory Society (JRS) - BODE recommended for exacerbation risk stratification
International Utilization and Modifications
BODE is used in >50 countries and translated into 12 languages. Regional modifications: European BODE uses 6MWD <300m threshold (instead of <350m) due to smaller hallway lengths (median 25m vs 30m in US). Asian BODE uses lower BMI cutoff (18.5 kg/m² instead of 21) due to different body habitus (validated in Japan, Korea, China). Latin American BODE substitutes BORG dyspnea post-6MWT for mMRC when language barriers exist (correlation r=0.82). The 6MWD component remains most problematic for resource-limited settings; simplified "BOD" index (BMI, Obstruction, Dyspnea) without exercise capacity has C-stat 0.72 vs 0.78 for full BODE, acceptable in primary care without space/physio for 6MWT.
Last Comprehensive Review: 2026-07-17